| Companies sponsors |
Johnson and Johnson (amivantamab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
EGFR Positive UK |
| |
Roy Castle Lung Cancer Foundation |
| Professional groups |
Association of Cancer Physicians |
| |
British Thoracic Oncology Group |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Associated public health groups |
None |
| Comparator companies |
Amarox (erlotinib) (confidentiality agreement not signed, not participating) |
| |
Aspire pharma (pemetrexed) (confidentiality agreement not signed, not participating) |
| |
AstraZeneca (gefitinib, osimertinib) (confidentiality agreement signed, participating) |
| |
Boehringer Ingelheim (afatinib) (confidentiality agreement not signed, not participating) |
| |
Bristol Myers Squibb (paclitaxel) (confidentiality agreement not signed, not participating) |
| |
Cipla EU (gefitinib) (confidentiality agreement not signed, not participating) |
| |
Eli Lilly and company (pemetrexed) (confidentiality agreement not signed, not participating) |
| |
Genus pharmaceuticals (pemetrexed, gefitinib) (confidentiality agreement not signed, not participating) |
| |
Glenmark Pharmaceutical (erlotinib) (confidentiality agreement not signed, not participating) |
| |
Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating) |
| |
Medac GmbH (vinorelbine) (confidentiality agreement not signed, not participating) |
| |
Merck, Sharp & Dohme (pembrolizumab) (confidentiality agreement signed, participating) |
| |
Mylan (erlotinib) (confidentiality agreement not signed, not participating) |
| |
Pfizer (pemetrexed, dacomitinib) (confidentiality agreement signed, participating) |
| |
Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating) |
| |
Roche (atezolizumab, erlotinib) (confidentiality agreement signed, participating) |
| |
Sandoz (cisplatin, docetaxel, pemetrexed, erlotinib, gefitinib) (confidentiality agreement not signed, not participating) |
| |
Seacross pharmaceuticals (docetaxel, paclitaxel, pemetrexed) (confidentiality agreement not signed, not participating) |
| |
Sun Pharmaceuticals (gemcitabine, pemetrexed) (confidentiality agreement not signed, not participating) |
| |
Synchrony Pharma (gemcitabine) (confidentiality agreement not signed, not participating) |
| |
Teva UK (paclitaxel) (confidentiality agreement not signed, not participating) |
| |
Zentiva (pemetrexed, erlotinib) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health – Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |